GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners.
In a lawsuit filed in federal court in Delaware Thursday, the UK pharma claimed Pfizer and BioNTech benefited from mRNA research conducted more than a decade before the pandemic. GSK said it secured the patents to those discoveries in 2015, when it acquired a portion of Novartis’ vaccines business.
“The foundation of Defendants’ technical and financial success with Covid-19 vaccines is the technology of GSK’s patented inventions,” GSK wrote in a complaint, which was first reported by Reuters.
Pfizer denied the allegations in a statement to Endpoints News. BioNTech acknowledged the lawsuit, but declined to comment.
“We are confident in our IP position around Comirnaty and intend to vigorously defend against these claims,” a Pfizer spokesperson said.
Pfizer and BioNTech have been involved in a drawn-out dispute with Moderna for almost two years, after the Cambridge, MA biotech accused them of copying parts of its vaccine technology patented between 2010 and 2016. Pfizer and BioNTech have denied those claims, and recently asked the US Patent Trial and Appeal Board (PTAB) to weigh in.
Comirnaty generated $11.2 billion in 2023 sales. GSK has asked the court to grant it a “reasonable royalty.”
“GSK is committed to taking appropriate action where necessary to protect the company’s intellectual property and believes that these patents provided the foundational technology used in Pfizer and BioNTech’s Covid-19 mRNA vaccines,” a GSK spokesperson said. “We are willing to license these patents on commercially reasonable terms.”
https://endpts.com/gsk-accuses-pfizer-and-biontech-of-mrna-patent-infringement/
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
NeuExcell Therapeutics Unveils Breakthrough in Stroke Treatment at ASGCT 2024
In a groundbreaking development, NeuExcell Therapeutics has revealed a significant breakthrough in its NXL-001 product for stroke treatment. The announcement was made at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, where the company...
Unraveling CRISPR Precision: BreakTag Illuminates Pathways to Improved Gene Editing
Introduction:The quest for precision in CRISPR-Cas9 gene editing takes a significant leap forward with the development of BreakTag, a method devised to enhance our understanding of DNA double-strand breaks (DSBs) induced by Cas9. This breakthrough, detailed in a...
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes– –If approved, vibegron will be the first and only beta-3 agonist for...
Herpes cure with gene editing makes progress in laboratory studies
Herpes simplex virus. Credit: CDCResearchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an...
Related Services
Plasmids GMP Services
AAV GMP Services
